CA 125: The past and the Future

  title={CA 125: The past and the Future},
  author={Ramona Bast and F.-J. Xu and Y.-H. Yu and Stephen D. Barnhill and Z. Zhang and G B Mills},
  journal={The International Journal of Biological Markers},
  pages={179 - 187}
  • R. Bast, F.-J. Xu, G. Mills
  • Published 1 October 1998
  • Biology, Medicine
  • The International Journal of Biological Markers
Over the last 15 years, substantial progress has been made in understanding the potential and the limitations of the CA 125 assay. More than 2000 papers have been published concerning laboratory and clinical studies of CA 125. The original CA 125 assay utilized the OC 125 antibody that recognizes the CA 125 epitope on a high molecular weight glycoprotein. Despite repeated attempts, the gene encoding the peptide component has not yet been cloned. Monoclonal antibodies have been raised against… 
The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects.
Increased clinical performance, in terms of better sensitivity and specificity in identifying epithelial ovarian cancer relapse, has been obtained by combined use of CA 125 with HE4, another ovarian cancer marker recently introduced in clinical use.
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
An in-depth review of the literature is provided to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer and the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors.
Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene
The cloning and expression of CA125 antigen opens the way to an understanding of its function in normal and malignant cells.
Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma
It is concluded that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.
Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging
An anti-CA125 monoclonal antibody and a single-chain variable fragment labeled with the positron-emitting radionuclide 64Cu are used for preclinical molecular imaging of CA125 expression in vivo for in vivo evaluation of cancer antigen 125 expression in EOC.
Beyond malignancy: the role of carbohydrate antigen 125 in heart failure
The biosynthesis, and potential insights of underlying pathophysiologies associated with CA-125 secretion in the scenarios of cardiac structural/functional alterations and HF, and further explored its current usage and roles in several recent reports are discussed.
Unexpected high serum level of CA 125 in male patient suffering from metastatic papillary carcinoma : a case
CA 125 is a high-molecular-weight (> 200 kDa) mucin-like glycoprotein recognized by the monoclonal antibody OC 125 that may be elevated in many other malignant diseases including adenocarcinoma of pancreas, lung and breast cancers and renal carcinoma.
Molecular Cloning of the CA125 Ovarian Cancer Antigen
The isolation of a long, but partial, cDNA that corresponds to the CA125 antigen and the deduced amino acid sequence has many of the attributes of a mucin molecule and was designated CA125/MUC16 (gene MUC16).


The CA 125 tumour-associated antigen: a review of the literature.
Serum CA 125 estimation is of clinical value in the pre-operative diagnosis and monitoring of ovarian malignancy and may be a prognostic indicator for this disease.
Coexpression of different antigenic markers on moieties that bear CA 125 determinants.
To determine how frequently determinants are coexpressed, macromolecular moieties containing CA 125 determinants have been isolated from ascites fluid of ovarian cancer patients by immunoaffinity chromatography and marked heterogeneity was observed between patients with regard to antigenic determinants that could be coexpressive.
Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer
The specificity of the CA 125 RIA is adequate in postmenopausal women to undertake a larger study to determine whether screening using CA 125 influences survival of patients with ovarian cancer.
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
Determination of CA 125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer, and rising or falling levels ofCA 125 correlated with progression or regression of disease in 42 of 45 instances.
OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
  • F. Xu, Y. Yu, C. Boyer
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
An elevated OVX1 level can alert oncologists to the possibility that ovarian cancer has persisted, despite the return of CA-125 to a normal range.
Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.
Data from gel electrophoresis, molecular size exclusion chromatography, and buoyant density ultracentrifugation suggest that the CA 125 antigenic determinant is composed of, at least in part, conformationally dependent peptide.
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.
To determine whether measurement of the levels of multiple tumor markers in the preoperative serum of women presenting with a pelvic mass distinguished benign from malignant disease better than the
Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer
In published trials, CA125 has been utilized to trigger ultrasound examination for the early detection of ovarian cancer. Although serum CA125 levels can be elevated prior to clinical detection of
Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer
An insight into the preclinical biology of ovarian neoplasia is provided that may help in designing methods for early detection of this disease, and the usefulness of the JANUS serum bank is demonstrated as a resource in evaluating serum tests.